Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

dapsone (Rx)Brand and Other Names:

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablet

  • 25mg
  • 100mg
more...

Dermatitis Herpetiformis

50 mg PO qDay, titrate to 300 mg qDay or higher to achieve desired effect

Reduce dose to minimum effective dose within the range of 50-300 mg qDay as soon as possible

Leprosy

100 mg PO qDay, in combination with other antileprosy drugs

Tuberculoid or Lepromatous Disease

100 mg PO qDay with rifampin 600 mg PO qDay

Pneumocystis (Carinii) Jiroveci (Off-label)

Prophylaxis

  • 100 mg PO qDay or divided BID as monotherapy, OR
  • 50 mg qDay in combination with weekly pyrimethamine and leucovorin

Treatment

  • 100 mg PO qDay in combination with trimethoprim for 21 days

Toxoplasmosis (Orphan)

Prophylaxis in severely immunocompromised patients (CD4 count <100)

Orphan indication sponsor

  • Jacobus Pharmaceutical Company, Inc; 37 Cleveland Lane, P.O. Box 5290; Princeton, NJ 08540

Dosage Forms & Strengths

tablet

  • 25mg
  • 100mg
more...

Leprosy

1-2 mg/kg PO qDay; not to exceed 100 mg/day in combination with other antileprosy agents 

Dosing considerations

  • Administer for 3 years (minimum) in combination with multidrug regimen (ie, rifampin)

Pneumocystis (Carinii) Jiroveci (Off-label)

Prophylaxis

  • >1 month old: 2 mg/kg PO qDay; not to exceed 100 mg/day, OR 
  • 4 mg/kg/dose PO qWeek; not to exceed 200 mg/week
  • Adolescents: 100 mg PO qDay or divided BID as monotherapy, OR 50 mg qDay in combination with weekly pyrimethamine and leucovorin

Treatment

  • >1 month old: 2 mg/kg PO qDay in combination with trimethoprim for 21 days
  • Adolescents: 100 mg PO qDay in combination with trimethoprim for 21 days
Next

Interactions

Interaction Checker

dapsone and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            1-10%

            Hemolysis

            Methemoglobinemia

            <1%

            Reactional states (ie, abrupt changes in clinical activity occurring during any leprosy treatment; classified as reversal of erythema nodosum leprosum reactions)

            Insomnia

            Headache

            Exfoliative dermatitis

            Photosensitivity

            Nausea

            Vomiting

            Anemia

            Leukopenia

            Agranulocytosis

            Hepatitis

            Cholestatic jaundice

            Peripheral neuropathy (usually in nonleprosy patients)

            Blurred vision

            Tinnitus

            SLE

            Previous
            Next

            Warnings

            Contraindications

            Hypersensitivity to drug or component

            Cautions

            May cause blood dyscrasias (eg, agranulocytosis); monitor closely

            Peripheral neuropathy may occur

            Toxic epidermal necrolysis and other dermatologic reactions may occur

            Use caution when treating patients with hypersensitivity to sulfonamides

            Bacterial and fungal superinfections may occur from prolonged treatments

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy category: C

            Lactation: Enters breast milk; not recommended (AAP Committee states "compatible with nursing")

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Sulfone; prevents normal bacterial utilization of para-aminobenzoic acid (PABA) for the synthesis of folic acid by acting as a competitive antagonist of PABA; it is bactericidal and bacteriostatic against Mycobacterium leprae

            Absorption

            Well absorbed

            Peak plasma time: 4-8 hr (after ingestion)

            Distribution

            Protein bound: 70-90% (dapsone); 99% (metabolite)

            Vd: 1.5 L/kg; throughout total body water and present in all tissues, especially liver and kidney

            Metabolism

            Hepatic P450 enzymes CYP2E1, CYP3A4

            Elimination

            Half-life: 28 hr

            Excretion: Urine (85%) as metabolites

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.